Table 5.

Novel icetexanes from Premna latifolin and in vitro cytotoxicity against human cancer.

IC50 (μg/mL)	HT-29	MCF-7	Hep-G2	A-549	A-431	PC-3	B-16F10	ACHN
80	0.04±0.02	1.11±0.23	2.13±1.92	6.05±0.71	33.40±1.95	3.24±0.38	6.41±5.47	4.83±0.32
81	2.17±0.71	6.02+0.00	0.18±0.06	58.24±6.8	10.14±1.39	3.77±0.18	5.71±0.28	0.40±0.04
82	15.25±0.54	11.49±0.53	18.92±0.99	9.85±0.54	21.22±0.74	9.27±0.67	19.65±0.69	24.50±0.9
83	12.15±2.29	1.11±0.23	13.29±0.64	12.21±0.32	22.55±0.30	17.38±0.4	22.91±0.53	1.40±0.13
Doxorubicin	21.54±0.29	2.01±0.03	1.63±0.04	2.68±0.28	4.23±0.20	1.71±0.11	21.22±0.74	1.29±0.02

Doxorubicin: positive control.